Costco Sells Cheap Drugs And Giant Muffins, HATCo Misplaces Its CEO Mid-Deal, And Pfizer Flirts With Trump’s Pharma-To-Table Movement

Hey all,

Happy Wednesday! My neighbors in Patterson, both teachers, are expecting their first child but are stressed by the lack of quality OBGYN care—nothing like the personalized experience my wife Lauren had with a private practice in NYC. As we on-board our first school district plan this month, I’m reminded about how while ZorroRX’s work is impactful there’s so much left to fix. 

Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

(Fierce Healthcare) Navitus Enables Cost-Plus Drug Pricing at Costco

Starting January, Navitus Health Solutions will offer cost-plus pricing for select prescriptions at Costco Pharmacies, disclosing drug acquisition costs, a fixed markup, and pharmacy service fees. The 100% pass-through PBM model emphasizes transparency and affordability, with same-day delivery via Instacart for members near a Costco location. So yes—you can now get your Mounjaro, a giant box of croissants for $7, and a 55-inch TV all dropped at your door in one absurdly efficient Instacart delivery. Full Article

(Modern Healthcare) HATCo CEO Transition and Summa Health Acquisition

Dr. Marc Harrison is stepping down as CEO of Health Assurance Transformation Corp. (HATCo) to become a strategic adviser as the company nears its $485 million acquisition of Summa Health. This leadership change comes as HATCo, launched by Harrison and General Catalyst CEO Hemant Taneja in 2023, works to reshape healthcare delivery through financial and operational transformation. The CEO role will remain vacant, with Daryl Tol promoted to president, and Kate Walsh poised to chair Summa’s board once the deal finalizes. Full Article

(Endpoints News) Pfizer, Trump, and Direct Drug Sales Program

Pfizer CEO Albert Bourla announced that major drugmakers are prepared to collaborate with former President Trump’s push for direct-to-consumer pharmaceutical sales and international reference pricing. As chair of PhRMA, Bourla emphasized that companies view Trump’s proposal—outlined in recent letters demanding “most favored nation” pricing and lower drug costs—as a viable strategy to make medications more affordable while maintaining U.S. industry competitiveness. Several firms, including Pfizer and Bristol Myers Squibb, have already launched or are planning similar discount programs, signaling a shift toward a more “pharma-to-table” model that could reshape how Americans access prescriptions. Full Article